BioMed Research International

Research Article

Comparison of Different First-Line Systemic Therapies in Advanced Biliary Tract Cancer Based on Updated Random Controlled Trials: A Systematic Review and Network Meta-Analysis

Table 3

Surface under the cumulative ranking curve values for overall survival.
TreatmentSUCRA
GemCis+Cediranib86.1
GemCis+Durvalumab80.4
GemCis+Merestinib74.7
GemOxa71.5
GemOxa+Erlotinib69.9
XELOX68.3
GemOxa+Panitumumab63.6
GemS160.3
GemCis60.2
S1Cis58
GemOxa+Cetuximab51.8
Gem38.7
Gem+Vandetanib38.5
FOLFIRINOX34.5
GemCis+Ramucirumab28.5
Vandetanib21.9
BSC17.3
FUFA17.3
S18.4
GemCis: gemcitabine plus cisplatin; GemOxa: gemcitabine plus oxaliplatin; GemS1: gemcitabine plus S-1; S1Cis: S1 plus cisplatin; XELOX: capecitabine plus oxaliplatin; BSC: best supportive care; FUFA: fluorouracil+folinic; FOLFIRINOX: oxaliplatin plus irinotecan plus infusional fluorouracil.